Our laboratory studies tumor-suppressor networks controlling apoptosis and senescence and how their disruption influences malignant behavior.
Scott W. Lowe, PhD
Chair, Cancer Biology & Genetics Program, SKI; Chair, Geoffrey Beene Cancer Research Center
Research FocusCancer biologist Scott Lowe uses genetically engineered mouse models to study how the genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create molecular vulnerabilities that may be targeted therapeutically.
EducationPhD, Massachusetts Institute of Technology
- A combinatorial strategy for treating KRAS-mutant lung cancer. Manchado E, Weissmueller S, Morris JP 4th, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. Nature. 2016 Jun 30;534(7609):647-51. Epub 2016 Jun 22.
- Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan CD, Gao J, Spitzer B, Bosbach B, Kastenhuber ER, Baslan T, Ackermann S, Cheng L, Wang Q, Niu T, Schultz N, Levine RL, Mills AA, Lowe SW. Nature. 2016 Mar 24;531(7595):471-475. doi: 10.1038/nature17157. Epub 2016 Mar 16.